0001140361-16-053437.txt : 20160217 0001140361-16-053437.hdr.sgml : 20160217 20160216173331 ACCESSION NUMBER: 0001140361-16-053437 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160217 DATE AS OF CHANGE: 20160216 EFFECTIVENESS DATE: 20160217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chase Pharmaceuticals Corp CENTRAL INDEX KEY: 0001509008 IRS NUMBER: 208866868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-257591 FILM NUMBER: 161430584 BUSINESS ADDRESS: STREET 1: 1823 K STREET, NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 202-223-7002 MAIL ADDRESS: STREET 1: 1823 K STREET, NW STREET 2: SUITE 520 CITY: WASHINGTON STATE: DC ZIP: 20006 D 1 primary_doc.xml X0707 D LIVE 0001509008 Chase Pharmaceuticals Corp 1825 K Street, NW Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 202-792-4621 DELAWARE None None Corporation true Douglas Ingram c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Executive Officer Director Thomas N. Chase c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Executive Officer Director Kathleen Clarence-Smith c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Executive Officer Stephen Cunningham c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Karoly Nikolich c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director John M. Reher c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Vikram Sudarsan c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Raphael Wisniewski c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Nayan Greg Parekh c/o Chase Pharmaceuticals Corporation 1825 K Street, NW, Suite 510 Washington, DC DC DISTRICT OF COLUMBIA 20006 Director Pharmaceuticals Decline to Disclose 06b false 2015-12-11 false true true true false 0 106650 0 106650 This filing covers the granting of options for Common Stock with an aggregate exercise price of $106,650.00, and the Common Stock issuable upon exercise thereof. false 3 0 0 0 false Chase Pharmaceuticals Corp /s/ Douglas Ingram Douglas Ingram Chief Executive Officer 2016-02-16